<DOC>
	<DOCNO>NCT02733016</DOCNO>
	<brief_summary>Seinäjoki Adult Asthma Study single-centre 12-year follow-up study total cohort 259 patient new-onset asthma diagnose adult age . The study divide two part : collection original cohort ( phase I ; n=259 ) follow-up visit ( phase II ; n=203 ) . The aim study increase understand diagnostics diagnostic process , organisation long-term asthma care , therapeutic outcome , prognosis factor affect prognosis new-onset asthma diagnose adult age .</brief_summary>
	<brief_title>Seinäjoki Adult Asthma Study</brief_title>
	<detailed_description>At baseline visit diagnostic study perform : spirometry , PEF ( peak expiratory flow ) follow-up , respiratory physiology measurement , laboratory , skin-prick , AQ20 ( Airways questionnaire 20 ) , 15D , background data . At follow-up visit , asthma status , co-morbidities ( chronic rhinitis obstruct nose , allergic rhinitis conjunctivitis , diabetes , hypertension , coronary heart disease , COPD ( chronic obstructive pulmonary disease ) patient-reported disease ) , medication ( include medication disease disease treat ) , control , severity lung function evaluate . In addition data gather visit , data asthma follow-up visit , exacerbation , hospitalisation , possible occupationally induced asthma prescribe asthma medication collect hospital clinic , primary health care , occupational health care private practice whole 12-year follow-up period . In addition , use medication realise , i.e. , medication buy pharmacy , retrieve . In addition asthma-specific factor , data include occupational , lifestyle socioeconomic factor follow-up visit .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>A diagnosis newonset asthma make respiratory specialist Diagnosis confirm least one follow objective lung function measurement FEV1 ( forced expiratory volume one second ) reversibility spirometry least 15 % 200 ml Diurnal variability ( ⩾20 % ) repeat reversibility ( ⩾15 % /60 l/min ) PEF followup A significant decrease FEV1 ( 15 % ) PEF ( 20 % ) response exercise allergen A significant reversibility FEV1 ( least 15 % 200 ml ) significant mean PEF response trial oral inhaled glucocorticoid Symptoms asthma Age ≥15 year Physical mental inability provide sign informed consent Diagnosis asthma age 15 year</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>